The benefit of MR-only radiotherapy treatment planning for anal and rectal cancers: A planning study by Bird, D et al.
Received: 26 May 2021 Revised: 22 July 2021 Accepted: 30 August 2021
DOI: 10.1002/acm2.13423
R A D I AT I O N O N C O L O G Y P H Y S I C S
The benefit of MR-only radiotherapy treatment planning
for anal and rectal cancers: A planning study
David Bird1,2 Michael G. Nix1 Hazel McCallum3,4 Mark Teo1
Alexandra Gilbert1,2 Nathalie Casanova1 Rachel Cooper1
David L. Buckley5 David Sebag-Montefiore1,2 Richard Speight1
Bashar Al-Qaisieh1 Ann M. Henry1,2
1 Leeds Cancer Centre, Leeds Teaching
Hospitals NHS Trust, Leeds, UK
2 Radiotherapy Research Group, Leeds
Institute of Medical Research, Leeds, UK
3 Northern Centre for Cancer Care, Newcastle
upon Tyne Hospitals NHS Foundation Trust,
Newcastle upon Tyne, UK
4 Centre for Cancer, Newcastle University,
Newcastle upon Tyne, UK
5 Biomedical Imaging, University of Leeds,
Leeds, United Kingdom
Correspondence
David Bird, Leeds Cancer Centre, Leeds




Cancer Research UK Centres Network
Accelerator, Grant/Award Number: A21993;




Introduction: Limited evidence exists showing the benefit of magnetic reso-
nance (MR)-only radiotherapy treatment planning for anal and rectal cancers.
This study aims to assess the impact of MR-only planning on target volumes
(TVs) and treatment plan doses to organs at risks (OARs) for anal and rectal
cancers versus a computed tomography (CT)-only pathway.
Materials and methods: Forty-six patients (29 rectum and 17 anus) under-
going preoperative or radical external beam radiotherapy received CT and T2
MR simulation. TV and OARs were delineated on CT and MR, and volumetric
arc therapy treatment plans were optimized independently (53.2 Gy/28 frac-
tions for anus,45 Gy/25 fractions for rectum).Further treatment plans assessed
gross tumor volume (GTV) dose escalation. Differences in TV volumes and
OAR doses, in terms of Vx Gy (organ volume (%) receiving x dose (Gy)), were
assessed.
Results: MR GTV and primary planning TV (PTV) volumes systematically
reduced by 13 cc and 98 cc (anus) and 44 cc and 109 cc (rectum) respec-
tively compared to CT volumes. Statistically significant OAR dose reductions
versus CT were found for bladder and uterus (rectum) and bladder, penile bulb,
and genitalia (anus).With GTV boosting, statistically significant dose reductions
were found for sigmoid,small bowel,vagina,and penile bulb (rectum) and vagina
(anus).
Conclusion: Our findings provide evidence that the introduction of MR (whether
through MR-only or CT-MR pathways) to radiotherapy treatment planning for
anal and rectal cancers has the potential to improve treatments. MR-related
OAR dose reductions may translate into less treatment-related toxicity for
patients or greater ability to dose escalate.
KEYWORDS
MRI-only planning, MR-only
This is an open access article under the terms of the Creative Commons Attribution License,which permits use,distribution and reproduction in any medium,provided
the original work is properly cited.
© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine
J Appl Clin Med Phy. 2021;1–13. wileyonlinelibrary.com/journal/acm2 1
2 BIRD ET AL.
1 INTRODUCTION
Magnetic resonance imaging (MRI)-only radiotherapy
treatment planning is the use of an MRI scan alone to
plan radiotherapy treatments. These techniques require
the generation of a “synthetic-computed tomography
(CT)” (computer generated) dataset as MRI does not
directly provide the patient density information required
to allow dose calculation that is usually obtained from
CT.1–3 MR-only planning techniques have developed
considerably in recent years, with commercial synthetic-
CT (sCT) solutions now available and specialist cen-
ters treating prostate cancers.1–3 However, a remaining
challenge to wide-spread adoption is the lack of evi-
dence within the literature demonstrating the impact of
MR-only radiotherapy treatment planning to patients, in
terms of improving treatments compared to standard
pathways.1
To the authors’ knowledge, only one study has
assessed the impact of MR-only radiotherapy treatment
planning on patient outcomes;finding prostate treatment
acute outcomes were similar to a CT-MR pathway.4 For
anal and rectal cancers, there is no evidence in the lit-
erature quantifying the impact of MR-only radiotherapy
treatment planning to patient treatments.
It is difficult to assess the impact of MR-only radio-
therapy treatment planning as standard pathways in rou-
tine clinical use include CT-only or CT-MR pretreat-
ment imaging. CT-only radiotherapy treatment planning
pathways are common in many centers, for example in
the UK, where dedicated radiotherapy MR provision is
relatively scarce.5 However, where the MR simulation
resources are available, CT-MR pathways are the pre-
ferred option.6 The central hypothesis for using MRI in
the radiotherapy treatment planning process, whether in
a CT-MR or MR-only pathway, is that the improved soft-
tissue contrast of MR allows improved visualization of
target volumes (TVs).7,8 For anal and rectal cancers, it is
hypothesized this could lead to more accurate definition
of tumors and therefore reduced radiotherapy TVs. This
is supported by diagnostic anal and rectal study findings
of net reductions in tumor volume when delineated on
MR versus CT.9,10
Comparing MR-only to CT-MR pathways, there are
a number of benefits which include reduced CT scan-
ning, streamlining clinical workflows, and removing CT-
MR registration uncertainties.7,8,11 As well as the logis-
tical and practical advantages, it is the removal of sys-
tematic CT-MR registration errors12 which could further
improve patient treatments.
Here, we aim to quantify the impact of MR-only radio-
therapy treatment planning on TVs and treatment plan
doses to organ at risk (OAR) for anal and rectal can-
cer treatments when compared to a routine CT-only
simulation pathway. We hypothesize that reduced MR-
only TVs should result in treatment plans with reduced
OAR doses if TV coverage is maintained. By compar-
ing MR-only and CT-only pathways, we are assessing
both the benefit of including MR in the treatment path-
way, which is also true of a CT-MR pathway and the
benefit of removing CT-MR pathway registration uncer-
tainties. We also hypothesize that gross tumor volume
(GTV) dose escalation planning13–15 would enhance
the benefit from MR-only versus CT-only planning due




This study recruited 46 patients with anal and rectal
cancer from a single center; 29 rectum and 17 anus;
24 male and 22 female, who were due to undergo
preoperative or radical volumetric arc therapy (VMAT)
external beam radiotherapy. Exclusion criteria included
patients with contra-indications to MR. Patient demo-
graphics and staging can be seen in Appendix A,
Table A1.This study is part of a wider MR-only radiother-
apy study: “Mri-only treAtmeNT planning for Anal and
Rectal cAncer radiotherapy” (MANTA-RAY), research
ethics committee reference: 18/LO/1298, ISRCTN Reg-
istry: ISRCTN82734641.
All patients received CT and T2-SPACE MR simula-
tion in the radiotherapy treatment position with matched
bladder filling and immobilization protocols. CT and MRI
scan parameters can be seen in Appendix A, Table A2.
For MR simulation, coil bridges were used to prevent
the coils from deforming the patient skin position. As
MR simulation was for research purposes it was sched-
uled for a time when the patient had a clinical appoint-
ment, and the MR scanner was available. The mean
time between planning CT and MR data acquisition was
15.1 days. The timings of the MR scans can be seen
in Appendix A, Table A1, where in total 41% of MR
scans were acquired prior to treatment starting, 69%
were acquired by the end of week 1 of treatment (frac-
tion 5), and 95% were acquired by the end of week 2 of
treatment (fraction 10).MR scans were rigidly registered
by an experienced clinical scientist specializing in image
registration, focussing on the rectum and anal canal,
to their paired CT datasets using the mutual informa-
tion registration algorithm in Raystation 8b (RaySearch
Laboratories, Stockholm, Sweden). MRs were resam-
pled to the CT frame of reference using Raystation
8b’s standard tri-linear resampling.A synthetic-CT (sCT)
scan was generated from each patient’s T2-SPACE MR
scan using a deep learning-based cGAN sCT model.
The cGAN sCT model and the CT and MR acquisi-
tion parameters have been previously described in the
literature.16
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TABLE 1 Target volume delineations and their definitions for anal and rectal cancers, including gross tumor volume (GTV), nodal gross
tumor volume (GTVN), boost gross tumor volume (GTVBoost), primary clinical target volume (CTVA), elective clinical target volume (CTVB/E),
nodal clinical target volume (CTVN), final clinical target volume (CTVF), primary planning target volume (PTV/PTVA), nodal planning target
volume (PTVN) and elective planning target volume (PTVE)
Anus Rectum
Target volume Definition Target volume Definition
GTV Macroscopic primary tumor only GTV CT: Macroscopic primary tumor extended to whole
lumen and identified nodal tumorsMR:
Macroscopic primary tumor only
CTVA T1/2: GTV + 1.0 cm enlarged to include the whole
of the anal canal and external sphincters
CTVA GTV + 1.0 cm
T3/4: GTV + 1.5 cm enlarged to include the whole
of the anal canal and external sphincters
CTVB Elective anatomically defined volume including the
mesorectum, pre-sacral, internal iliac and pelvic
side-wall nodes
PTVA CTVA + 1.0 cm CTVF CTVA + CTVB
GTVBoost GTV + 0.5 cm PTV CTVF + 1.5 cm (anterior) and 1 cm (all other
directions)
GTVN Identified nodal tumors GTVBoost GTV + 1.0 cm
CTVN GTVN + 0.5 cm X
PTVN CTVN + 0.5 cm
CTVE Elective anatomically defined volume including the
mesorectal, bilateral inguinal, internal, and
external iliac nodes to 2 cm above the lower
border of sacroiliac joints, presacral nodes (or
1.5 cm superior from the most superior GTV)
PTVE CTVE + 0.5 cm
2.2 TV and OAR delineation
All TVs (defined in Table 1) were delineated on CT and
T2 MR simulation scans separately according to our
center’s clinical protocol, apart from GTVBoost volumes
which were chosen according to clinical trials assessing
GTV dose escalation.13–15 All patients had diagnostic
MR available, and patients with anal cancer additionally
had diagnostic PET-CT available to assist delineations
through side-by-side comparisons to the planning scan
as per our center’s clinical protocol. These diagnostic
scans were unsuitable for registration and further use in
the study.
CT TVs, as used for each patient’s clinical treatment,
were delineated by the treating consultant clinical oncol-
ogist. MR GTV delineations were undertaken by one of
three consultant clinical oncologists specializing in anal
and rectal cancer treatments with experience of inter-
preting T2 MR sequences for ano-rectal tumor delin-
eations. MR GTVs were undertaken 2+ months after
CT delineations to avoid potential recollection bias. All
GTV delineations were undertaken using all clinically
available information, apart from the other scan (CT or
MRI). An experienced clinical scientist specializing in
radiotherapy imaging created all other MR TVs through
expansions and manual adjustments, all matching the
CT clinical pathway (Table 1). For elective CTVs (rec-
tum and anus), the CT CTV was rigidly transferred to the
MR and manually adjusted to anatomical boundaries,
accounting for anatomical changes between CT and
MR, for example differences in the mesorectum bound-
ary.
OARs were delineated on CT and MR by experi-
enced dosimetrists and included bladder, small bowel,
sigmoid, penile bulb, vagina, uterus (rectum and anus),
bowel cavity (rectum only), femoral heads, and genitalia
(anus only). All OARs were assessed and amended as
required by an experienced clinical scientist to ensure
accuracy. Genitalia OARs (delineated from anatomical
landmarks) were delineated on CT and rigidly trans-
ferred to MR to ensure consistency. Penile bulb, vagina,
and uterus were delineated on MR and transferred to
CT (rigid registration: penile bulb, deformable regis-
tration: vagina and uterus). These registrations were
undertaken and validated through visual assessment
by an experienced physicist who specializes in MR-CT
registrations. The decision to transfer the OARs from
MR was made because of the poor visualization of
these OARs on CT. All MR TVs and OARs were rigidly
transferred to the sCT from the MR to allow radiotherapy
treatment planning to occur.
2.3 TV analysis
Volumetric and positional TV analyses were under-
taken. The positional analysis compared the overlap of
CT and MR volumes using sensitivity and specificity
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measures—the volume overlap between CT and MR
contours, as a percentage of the volume of CT (sen-
sitivity) or MR (specificity) respectively.
2.4 Radiotherapy treatment planning
VMAT plans were created and optimized for each
patient’s CT and sCT scan independently by a single
experienced clinical scientist following the center’s clin-
ical protocol. Plans were optimized for the delineated
TVs and OARs, in Raystation 8b, using the collapsed
cone photon algorithm on a dose grid of 3 × 3 × 3 mm3
and beam arrangements seen in Appendix A, Table A3.
Rectum plans were prescribed as 45 Gy in 25 fractions
to the primary PTV, and anus plans were prescribed
a three dose level technique with 53.2 Gy, 50.4 Gy,
and 40.0 Gy in 28 fractions to the primary, nodal, and
elective PTVs, respectively (subsequently referred to as
“standard” plans). To increase the homogeneity of pre-
scription doses, we opted to standardize the dose pre-
scription for each cancer site (in practice some patients
received 25 Gy in 5 for rectal cancers and 50.4 Gy for
T1/2N0 anal cancers).
Dose escalation plans (“Boost” plans) were also gen-
erated to assess the impact of dose escalation to GTV-
based (“GTVBoost”) structures with 61.6 Gy and 55 Gy
prescribed for anus and rectum, respectively. GTVBoost
prescription doses were chosen according to clinical tri-
als assessing GTV dose escalation.13–15 Boost plans
were created by copying each standard plan, adding
optimization constraints and objectives for the GTV-
Boost contour and re-optimizing the plan. All treatment
plan optimization parameters and clinical objectives can
be seen in Appendix A, Tables A4 and A5.
All plans were optimized to meet target coverage
constraints while minimizing OAR doses. The planning
protocol was adapted to include a high mandatory
coverage goal for all PTVs, with the rationale that high
target coverage prevents subjective, plan specific, local
areas of poor PTV coverage within the plan objectives
which may impact OAR dose reductions.
2.5 VMAT plan analysis
As all plans had strict TV coverage criteria, plan assess-
ment focussed on the dosimetric differences to OARs
when TV coverage was achieved. Each OAR was
assessed in terms of the Vx (%), the volume of the
organ as a percentage of the total organ volume, receiv-
ing x Gy in dose. DVH statistics were collected for 95%,
90%, 80%, 70%, and 60% of the prescription dose for
each standard plan and compared between CT and MR.
These dose levels were chosen to allow a more com-
prehensive analysis of the dose-volume relationship for
each OAR. Dose levels lower than 60% of the pre-
scription dose were not assessed. For boost plans, DVH
assessments focussed on the dose levels introduced by
the GTVboost prescription (52.25 Gy,49.5 Gy,and 45 Gy
[rectum] and 58.5 Gy, 55.4 Gy, and 53.2 Gy [anus]).
For standard and boost plans,collected DVH statistics
were filtered such that if both the CT and MR DVH statis-
tic (Vx) were ≤1% then the statistic was removed from
the analysis.This removed cases where the TV and OAR
were separated sufficiently that the OAR was not receiv-
ing that dose level on either plan.In all cases,the femoral
heads received a dose less than 60% of the prescription
and consequently were removed from the analysis.
2.6 Statistical analysis
Linear mixed effects (LME) models in STATA17 were
applied to TV volume and OAR dose analyses to estab-
lish statistically significant differences in TVs and OAR
doses attributable to the change in modality, CT, and
MR. Separate models were applied to each cancer site
cohort (anus and rectum) and TV/OAR dose level indi-
vidually. DVH statistic differences were only modeled if
five or more patient’s results were present.TV LME mod-
els used volume (cc) as the dependant variable, modal-
ity (CT and MR), sex (male and female), and staging (1,
2, 3, or 4) as fixed effects independent variables. The
OAR dose LME models used DVH statistic, Vx, as the
dependant variable, modality (CT and MR), sex (male
and female), and organ volume as fixed effect indepen-
dent variables. Patient was a random effect indepen-
dent variable in all models. Organ volume was included
to account for impact of variations in organ volume (for
example the bladder) on the DVH statistics.
3 RESULTS
TV comparisons for both anal and rectal cancers found
a statistically significant systematic reduction in MR
GTV (12.6 cc and 43.6 cc respectively), primary PTV
(98.1 cc and 109.1 cc respectively), and GTVBoost
(22.3 cc and 95.2 cc respectively) volumes compared to
CT. Table 2 shows the MR TV volume differences ver-
sus CT, their statistical significances and the positional
overlap between MR and CT. Figure 1 shows a visual
example of the changes in GTV, CTVA, and primary
PTV between MR and CT for a single anus and rectum
cancer case. Figure 2 shows box plots of the volumes
of the anal and rectal radiotherapy TVs on CT an MR.
For anus plans, statistically significant dosimetric
reductions were found on MR (vs.CT) plans for the blad-
der (3.8%), penile bulb (∼10%), and genitalia (∼4%).
Systematic dose reductions that had not reached sta-
tistical significance were also found for the vagina
(∼13%). For rectum plans, statistically significant dosi-
metric reductions were found on MR (vs. CT) plans for
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TABLE 2 The magnetic resonance (MR) target volume (TV) differences in volume compared to computed tomography (CT) and the mean
sensitivity and specificity overlap for each target volume between MR and CT over the whole patient cohort, where effect size is the systematic
difference between MR and CT volumes (a negative value indicates that MR is smaller than CT). Bold effect size values indicate statistically
significant confidence intervals
Mean overlap
MR volume effect size versus CT
(95% confidence intervals) (cc)






Rectum GTV −43.6 (−54.8 to −32.5) −56.5 36.4 93.7
CTVA −95.2 (−116.3 to −74.3) −37.1 57.8 95.2
CTVB −11.7 (−17.1 to −6.3) −2.6 94.5 97.6
CTVF −66.0 (−80.7 to −51.4) −12.4 85.7 98.3
PTVA −109.1 (−131.1 to −87.2) −8.6 90.3 99.0
GTVBoost −95.2 (−116.3 to −74.3) −28.2 57.8 95.2
Anus GTV −12.6 (−19.5 to −5.7) −46.6 32.5 80.3
CTVA −47.7 (−72.4 to −22.9) −20.7 66.0 87.1
PTVA −98.1 (−146.1 to −50.1) −19.3 72.4 92.0
GTVN −3.0 (−7.6 to 1.5) −15.7 53.5 73.0
CTVN −9.2 (−20.3 to 1.9) −12.5 70.7 84.5
PTVN −24.5 (−47.0 to −2.1) −16.5 74.4 91.9
CTVE-all −35.0 (−56.6 to −13.4) −4.0 89.8 94.7
PTVE-all −106.8 (−144.7 to −68.9) −5.9 88.1 94.2
GTVBoost −22.3 (−33.7 to −10.9) −34.4 46.9 81.8
Abbreviations: CTVA, primary clinical target volume; CTVB/E, elective clinical target volume; CTVF, final clinical target volume; CTVN, nodal clinical target volume; GTV,
gross tumor volume; GTVBoost, boost gross tumor volume; GTVN, nodal gross tumor volume; PTV/PTVA, primary planning target volume; PTVE, elective planning
target volume; PTVN, nodal planning target volume.
F IGURE 1 Comparison of anus (right) and rectum (left) cancer
GTVs (red), CTVAs (orange), and primary PTVs (blue) for MR (bold)
versus CT (dotted) delineations on CT (top) and T2 SPACE MR
(bottom) datasets
the bladder (∼5%) and uterus (∼13%). Systematic dose
reductions that had not reached statistical significance
were found for the penile bulb (∼6%). Table 3 shows
the dosimetric differences to OARs in standard plans
between MR and CT.
For rectum boost plans, statistically significant dosi-
metric reductions were found for the bladder (4.6%),
small bowel (∼3.5%), sigmoid (∼6%), vagina (13.6%),
uterus (∼20%), and penile bulb (11.5%). For anus plans,
statistically significant dosimetric reductions were found
for the vagina (4.4%) and penile bulb (15.4%). Table 4
shows the dosimetric differences to organs in boost
plans between CT and MR.
4 DISCUSSION
A challenge to wide-spread adoption of MR-only radio-
therapy treatment planning is the lack of evidence
within the literature demonstrating its benefit in terms
of improving treatments. Here, we provide evidence that
utilizing an MR-only radiotherapy pathway for anal and
rectal cancers makes statistically significant changes to
TV volumes and treatment plan OAR doses, in terms
of reductions in volume (∼100 cc for PTV/PTVA) and
dose-volume (5%–20%) compared to a CT-only path-
way. These TV and treatment plan changes can be
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F IGURE 2 Box-plots comparing the volumes of treatment target volumes for anal cancers (top left), rectal cancers (top right), and all GTVs
(bottom middle) on CT (dark grey) and MR (light grey) including the median, interquartile range, and outlier values.
considered evidence of benefit as smaller TVs result
in less irradiated tissue, and lower normal tissue doses
can be expected to lead to reduced organ toxicities.18 It
is important to recognize that while we have compared
an MR-only radiotherapy pathway to a CT-only pathway,
many centers with radiotherapy MR provision employ
a CT-MR pathway. Our findings are more difficult to
apply to CT-MR pathways which, compared to MR-only,
introduce co-registration errors. As such the treatment
changes, we present here would likely be smaller for a
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TABLE 3 The magnetic resonance (MR) dosimetric differences to organs at risks (OARs) in standard plans for anal and rectal cancer
treatments, where volume effect size is the systematic difference in volume of each organ receiving x Gy of dose on MR versus computed
tomography (CT) (a negative value indicated a lower dose on MR compared to CT). Bold effect size values indicate statistically significant

















V80% 7 −0.6 (−5.6 to 4.4) 28 −5.3 (−8.2 to −2.4)
V70% 17 −3.8 (−6.4 to −1.2) 28 −5.2 (−8.2 to −2.3)
V60% 17 −4.1 (−8.6 to 0.3) 28 −5.2 (−8.2 to −2.2)
Small bowel V95% 0 – 23 −1.0 (−5.4 to 3.4)
V90% 1 – 23 −0.9 (−5.6 to 3.7)
V80% 3 – 23 −0.9 (−5.6 to 3.7)
V70% 13 2.0 (−2.0 to 5.9) 23 −0.8 (−6.1 to 4.4)
V60% 14 5.0 (−0.7 to 10.7) 23 −0.8 (−6.7 to 5.0)
Sigmoid V95% 2 – 29 −3.0 (−7.1 to 1.1)
V90% 3 – 29 −2.7 (−6.9 to 1.5)
V80% 5 −1.5 (−6.5 to 3.5) 29 −1.8 (−6.3 to 2.7)
V70% 17 −2.7 (−9.6 to 4.3) 29 −1.0 (−5.7 to 3.7)
V60% 17 −2.5 (−11.1 to 6.0) 29 −0.6 (−5.7 to 4.5)
Vagina V95% 8 −12.5 (−29.2 to 4.2) 14 0.7 (−1.3 to 2.6)
V90% 8 −12.9 (−28.9 to 3.2) 14 0.5 (−1.3 to 2.3)
V80% 8 −16.0 (−33.4 to 1.4) 14 0.1 (−1.3 to 1.6)
V70% 8 −3.5 (−7.7 to 0.7) 14 0.2 (−1.1 to 1.5)
V60% 8 1.1 (−0.5 to 2.7) 14 0.7 (−0.7 to 2.1)
Uterus V95% 2 – 13 −15.9 (−24.4 to −7.4)
V90% 2 – 13 −14.9 (−23.8 to −6.1)
V80% 3 – 13 −13.8 (−22.6 to −4.9)
V70% 7 −10.4 (−27.3 to 6.6) 13 −12.8 (−21.3 to −4.3)
V60% 7 2.6 (−24.3 to 29.6) 13 −11.8 (−20.3 to −3.2)
Penile Bulb V95% 9 −11.2 (19.9 to −2.5) 6 −7.3 (−27.2 to 12.5)
V90% 9 −9.6 (−16.4 to −2.7) 9 −5.4 (−18.4 to 7.6)
V80% 9 −8.3 (−15.5 to −1.2) 9 −6.0 (−18.2 to 6.2)
V70% 9 −8.4 (−16.2 to −0.7) 9 −7.3 (−18.8 to 4.2)
V60% 9 −8.8 (−16.8 to −0.7) 10 −9.7 (−21.5 to 2.1)
Genitalia V95% 5 −4.8 (−11.0 to 1.3) –
V90% 5 −5.2 (−12.0 to 1.6)
V80% 6 −5.1 (−11.5 to 1.3)
V70% 11 −4.0 (−7.5 to −0.5)
V60% 17 −3.5 (−5.7 to −1.3)
CT-MR pathway. However, our findings can also broadly
be applied to MR-CT pathways and therefore add to a
growing body of evidence that the introduction of MR
can improve treatments, whether through MR-only or
CT-MR pathways,which has not previously been shown
in the literature in these terms.
Our findings showed that the improved soft tissue
visualization of MR translated into reduced TV volumes
for both anal and rectal cancers. GTV volumes were
reduced significantly as suggested by diagnostic CT ver-
sus MR comparisons in the literature,9,10 and this trans-
lated through to reductions in primary PTV volumes.The
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TABLE 4 The MR dosimetric differences to organs at risks (OARs) in boost plans for anal and rectal cancer treatments, where volume
effect size is the systematic difference in volume of each organ receiving x Gy of dose on magnetic resonance (MR) versus computed
tomography (CT) (a negative value indicated a lower dose on MR compared to CT). Bold effect size values indicate statistically significant
confidence intervals. “Number of patients” is the number of patients whose dose-volume histogram (DVH) statistics were <1% on both CT and













Vx effect size (95%
confidence intervals) (%)
Bladder
V55.4 0 – V49.5 11 −3.0 (−6.1 to 0.1)
V53.2 2 – V45 27 −4.6 (−7.6 to −1.7)
Small bowel V58.5 0 – V52.25 8 −3.4 (5.9 to −0.8)
V55.4 0 – V49.5 8 −3.6 (−6.7 to −0.5)
V53.2 0 – V45 23 −1.0 (−3.9 to 1.9)
Sigmoid V58.5 0 – V52.25 16 −6.4 (−9.1 to −3.7)
V55.4 0 – V49.5 16 −6.4 (−9.6 to −3.3)
V53.2 1 – V45 29 −4.6 (8.9 to −0.4)
Vagina V58.5 7 −4.4 (−8.0 to −0.8) V52.25 13 −13.6 (−26.3 to −0.9)
V55.4 7 −8.7 (−22.0 to 4.7) V49.5 14 −6.9 (−17.1 to 3.2)
V53.2 8 −11.1 (−28.3 to 6.0) V45 14 −1.7 (−5.7 to 2.2)
Uterus V58.5 0 – V52.25 11 −19.8 (−30.7 to −9.0)
V55.4 1 – V49.5 12 −21.9 (−32.7 to −11.2)
V53.2 2 – V45 13 −19.6 (−26.9 to − 12.3)
Penile Bulb V58.5 3 – V52.25 3 –
V55.4 7 −22.4 (−49.2 to 4.4) V49.5 4 –
V53.2 8 −15.4 (−30.3 to −0.5) V45 6 −11.5 (−34.3 to −11.3)
Genitalia V58.5 2 – –
V55.4 3 –
V53.2 4 –
resultant ∼100 cc reduction in PTV volume is a sig-
nificant amount of tissue which will be spared a high
(prescription level) dose. Both cancer sites also saw
significant reductions in anatomically defined CTVB/E
volumes from CT to MR. A visual assessment of the
CTVs showed that this was due to an improvement in
tissue visualization at the mesorectum anterior border,
where it is difficult to define the mesorectum, vagina,
and seminal vesicles borders on CT.This soft-tissue con-
trast improvement has the potential to also improve clin-
ician confidence, speed, and inter-observer variability
when delineating, although assessing this was beyond
the scope of this study. The GTVBoost volume reduc-
tions also add evidence that MR-based radiotherapy
treatment planning may have a greater impact on boost
plans. Our positional differences between MR and CT
delineated TVs showed the specificity of TVs (overlap
as a percentage of the MR volume) was much higher
than the sensitivity (overlap as a percentage of the
CT volume), suggesting that MR volumes are not only
smaller than CT, but also predominantly within the CT
volumes which adds strength to the hypothesis that MR
improves the visualization of TVs. It is notable that our
delineation protocol for rectum GTVs varied between CT
and MR, where CT GTVs included the whole lumen but
MR GTVs included the visible tumor only. This was due
to the soft tissue contrast of MR enabling a systematic
change in delineation protocol through improved visual-
ization,and it is the impact of this improved visualization
that we have quantified here.
Our standard treatment plan analysis found statis-
tically significant reductions in OAR doses for both
cancer sites. This provides evidence that MR-only
radiotherapy treatment planning makes a quantitatively
significant improvement to treatment plans compared to
CT-only pathways. The OAR dose changes that we saw
here are logical. For standard plans we saw that the
organs closest to the primary GTV—the sexual organs
for anal cancers,19 and the bladder and uterus for
rectum cancers had statistically significant systematic
dose reductions, whereas we saw no change to the
small bowel dose which is predominantly the organ
furthest from the GTV. There were also a number of
organs that had systematic dose reductions that had
not reached statistical significance. While less definitive,
these findings should also be viewed positively and
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suggest that there may be additional benefit in a larger
population. Our dose escalation (boost) plan analysis
also suggests that MR boost plans were able to improve
the sparing of OARs very close to the primary GTV, for
example the vagina and penile bulb for anal cancers,
but that for rectal cancers there was a much wider dose
reduction to the majority of OARs, including small bowel
and sigmoid. This can be explained by the much larger
GTVBoost volume for rectal cancers compared to anal
cancers, the central position of the rectum in the pelvic
cavity, and the differences in the elective CTV standard
plan dose prescription between rectal and anal cancers.
There are limitations to this study. It is known that
some tumor shrinkage occurs during treatment as
shown by Van den Begin20 who found for rectal cancers
MRI GTVs versus a pretreatment baseline volume that
tumor shrinkage of up to 10% after 1 week (five frac-
tions) and 26% after 2 weeks (10 fractions) can occur.
Logistical challenges meant it was necessary to accept
acquiring MR scans after patient treatments had started,
and this had the potential to bias our findings. How-
ever, to assess this, we stratified our CT to MR GTV
volume findings by MR acquisition date and found that
for both anal and rectal cancers, there was no correla-
tion between MR scan timing and average GTV reduc-
tion (pretreatment = −53%, week 1 = −44%, and week
2 = −56%). It is possible that some component of the
tumor reduction we identified here has been caused by
treatment; however, the GTV reductions seen here are
much larger than those demonstrated due to treatment
by Van den Begin,and consequently, it is more likely that
the large reduction in GTV caused by improved MR tis-
sue visualization substantially outweighs the impact of
treatment GTV changes.
It is possible that the OAR dose reductions found
here may be insufficient to produce meaningful toxic-
ity reductions. Future work would benefit from assess-
ing the impact of these dose reductions on normal tis-
sue complication probability for the organs highlighted
here. However, this is a non-trivial assessment to under-
take, and as such it was outside the scope of this study
to assess dose-toxicity relationships. We also did not
assess OAR changes in relation to the position of the
tumor; however our use of filtering DVH statistic was
designed to reduce the impact of this on our analysis.
Further work would be beneficial to investigate whether
it is possible to prospectively identify patients who would
benefit most from MR-only planning, prior to simulation.
A challenge with planning studies is ensuring that treat-
ment plan differences are not due to inter-operator vari-
ability in delineations and planning. Here, there was the
potential for inter-operator variability as the clinicians
delineating GTVs differed between CT and MR. How-
ever, we aimed to avoid significant inter-operator vari-
ability through delineations being undertaken by experi-
enced consultants, following our local clinical protocols
with additional training, stricter planning constraints, and
oversight by a single physicist for consistency. The sim-
ulation protocols also minimized our OAR volume differ-
ences and the uncertainty this can cause between CT
and MR as seen in Appendix A, Table A6.
There is also an argument that reducing TVs due to
a change in imaging modality could have a negative
effect on tumor control probability as our understand-
ing of required treatment dose levels stems from CT-
based targets and the reduction of the TVs is in essence
removing implicit margins caused by a lack of contrast
on CT. This argument highlights the need for caution
when assessing new techniques such as MR-only plan-
ning.
Our findings suggest that MR-only radiotherapy treat-
ment planning can be considered to be an improvement
in the personalization of radiotherapy treatments, com-
pared to CT-only,as it allows clearer visualization of indi-
vidual patient anatomy. Here, we aimed to assess the
impact of MR-only radiotherapy treatment planning on
TVs and treatment plan doses to OARs for anal and rec-
tal cancers when compared to a routine CT-only path-
way. Our findings provide evidence that MR-only radio-
therapy treatment planning for anal and rectal cancers
results in statistically significant reductions in TV vol-
umes and reduced doses to a number of OARs. This
suggests that patients could benefit from MR-only (or
CT-MR) radiotherapy treatment planning with the poten-
tial for improved patient outcomes if OAR dose reduc-
tions translate into less treatment-related toxicity or sup-
port GTV dose escalation.
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APPENDIX A
TABLE A1 Anal and rectal cancer patient demographics
Anus (total 17) Rectum (total 29)
Age Mean (range) 63 (47–76) 63 (38–78)
Sex Male 9 15
Female 8 14




MR scan acquired Pretreatment 6 13
Fraction 1–5 4 9
Fraction 6–10 6 6
Fraction 11–13 1 1
TABLE A2 computed tomography (CT) and magnetic
resonance (MR) simulation scan parameters
MR Make & Model Siemens Aera 1.5 T
Sequence 3D







Echo train length 134
Field of view
(superior-inferior)
Inferior: 2 cm inferior of genitalia
Superior: superior aspect of L5
vertebra or greater as required
Field of view (Axial) 450 × 450 mm2
CT Make & Model Philips Brilliance Big Bore





TABLE A3 Treatment plan beam arrangement and prescription




Prescription type “Average Dose”
Isocenter Position Center of PTV
Energy (MV) 6MV FFF
Beam arrangement 360◦ arc (starting at 180◦)






PTV 53.2 Gy in 28
fractions
45 Gy in 25
fractions
PTVN 50.4 Gy in 28
fractions
X










GTVBoost 61.6 Gy in 28
fractions
55 Gy in 25
fractions
Abbreviations: GTVBoost, boost gross tumor volume; PTV, primary planning tar-
get volume; PTVE, elective planning target volume; PTVN, nodal planning target
volume; VMAT, volumetric arc therapy.
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volume/OAR Objective Description Target volume/OAR Objective Description
Standard plan PTV Min dose 45 Gy PTV Min dose 53.2 Gy
Uniform dose 45 Gy Uniform dose 53.2 Gy
Patient external Dose fall off High: 45 Gy,
Low: 25 Gy,
Distance: 1.5 cm
PTVN - PTV Min dose 50.4 Gy
Dose fall off High: 25 Gy,
Low: 0 Gy,
Distance: 6.0 cm
Uniform Dose 50.4 Gy
Bladder-PTV Max DVH 20.0 Gy to 30% Dose fall off High: 53.2 Gy,
Low: 50.4 Gy,
Distance: 2.0 cm
Bowel cavity -PTV Max DVH 20.0 Gy to 30% PTVE - (PTV+PTVN) Min dose 40 Gy
Penile bulb - PTV Max DVH 20 Gy to 35% Dose fall off High: 53.2 Gy,
Low: 40.0 Gy,
Distance: 2.0 cm
Uterus - PTV Max DVH 20 Gy to 35% Patient external Dose fall off High: 53.2 Gy,
Low: 25 Gy,
Distance: 1.5 cm
Vagina - PTV Max DVH 20 Gy to 35% Dose fall off High: 53.2 Gy,
Low: 0 Gy,
Distance: 6.0 cm
X Bladder - PTVs Max DVH 20 Gy to 35%
Small bowel - PTVs Max DVH 20 Gy to 35%
Femoral heads - PTVs Max DVH 20 Gy to 35%
Genitalia - PTVs Max DVH 20 Gy to 35%
Penile bulb - PTVs Max DVH 20 Gy to 35%
Uterus - PTVs Max DVH 20 Gy to 35%
Vagina - PTVs Max DVH 20 Gy to 35%
Boost plan objectives GTVBoost Min dose 55.0 Gy GTVBoost Min dose 61.6 Gy
Uniform dose 55.0 Gy Uniform dose 61.6 Gy
PTV Dose fall off High: 55.0 Gy,
Low: 45.0 Gy,
Distance: 1.0 cm
PTV Dose fall off High: 61.6 Gy,
Low: 53.2 Gy,
Distance: 1.0 cm
Abbreviations:GTVBoost,boost gross tumor volume;PTV,primary planning target volume;PTVE,elective planning target volume;PTVN,nodal planning target volume.
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volume/OAR Objective Goal Target volume/OAR Objective Goal
Standard plan PTV V42.75 Gy (95%) >99.5% PTV D99.5% ≥95% (50.54 Gy)
V47.25 Gy
(105%)
<0.1% D50% ≥99% (52.6 Gy) and ≤101%
(53.7 Gy)
D50% ≥99% (44.55 Gy) and
≤101% (45.45 Gy)
D1% ≤105% (55.9 Gy)
Bowel cavity V20Gy <400 cc PTVN − PTV D99.5% ≥95% (47.9 Gy)
V30Gy <250 cc D50% ≤105% (55.9 Gy)
V43Gy <200 cc PTVE − (PTV+ PTVN) D99.5% ≥95% (38.0 Gy)
Bladder V35Gy <45% D50% ≤110% (44.0 Gy)




Bladder D50% ≤45 Gy
D35% ≤50 Gy
D5% ≤55 Gy
Femoral heads D50% ≤45 Gy
D35% ≤50 Gy
D5% ≤55 Gy





GTVBoost V52.25 Gy (95%) >99.5% GTVBoost D99.5% ≥95% (58.1 Gy)
V52.25 Gy
(105%)
<0.1% D50% ≥99% (61.0 Gy) and ≤101%
(62.2 Gy)
Abbreviations:GTVBoost,boost gross tumor volume;PTV,primary planning target volume;PTVE,elective planning target volume;PTVN,nodal planning target volume.
TABLE A6 Organ volumes on computed tomography (CT) and magnetic resonance (MR) for anal and rectal cancer patients including:
Mean (range, SD)
CT (cc) MR (cc) Difference (cc)
Rectum Bladder 275 (48–962, 170) 305 (32–746, 167) 30 (−266–458, 169)
Sigmoid 108 (23–309, 76) 92 (10–310, 77) −16 (−126–28, 34)
Small bowel 264 (0–741, 179) 225 (0–659, 148) −30 (−406–202, 125)
Penile bulb 6 (2–11, 2) 6 (2–11, 2) 0 (0, 0)
Vagina 18 (9–41, 9) 15 (8–31, 7) −3 (−10–1, 3)
Uterus 61 (9–116, 31) 57 (22–108, 28) −4 (−20–15, 10)
Anus Bladder 318 (95–813, 186) 324 (44–891, 202) 6 (−180–322, 13)
Sigmoid 156 (36–381, 97) 127 (14–366, 84) −29 (−99–61, 43)
Small bowel 284 (27–818, 212) 212 (50–527, 143) −72 (−292–136, 109)
Penile bulb 5 (2–11, 3) 5 (2–11, 3) 0 (0, 0)
Vagina 13 (8–25, 6) 12 (5–18, 5) −2 (−7–2, 3)
Uterus 34 (13–64, 16) 31 (14–55, 12.5) −3 (−9–6, 5)
Genitalia 298 (58–686, 181) 297 (56.8-686, 181) 0 (0, 0)
